Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · IEX Real-Time Price · USD
0.752
-0.076 (-9.13%)
At close: Apr 19, 2024, 3:53 PM
0.762
+0.010 (1.33%)
After-hours: Apr 19, 2024, 7:49 PM EDT
Biodexa Pharmaceuticals Stock Forecast
BDRX's stock price has decreased by -96.65% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for BDRX stock has a target of 8.00, which predicts an increase of 963.83% from the current stock price of 0.75.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 8, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for BDRX is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '24 | Apr '24 |
|---|---|---|
| Strong Buy | 1 | 1 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +963.83% | Feb 8, 2024 |
Financial Forecast
Revenue This Year
642.92K
from 699.00K
Decreased by -8.02%
Revenue Next Year
n/a
from 642.92K
EPS This Year
-0.80
from -6.20
EPS Next Year
-0.00
from -0.80
Revenue Forecast
| Revenue | 2023 |
|---|---|
| High | 928,610 |
| Avg | 642,916 |
| Low | 368,705 |
Revenue Growth
| Revenue Growth | 2023 |
|---|---|
| High | 32.8% |
| Avg | -8.0% |
| Low | -47.3% |
EPS Forecast
| EPS | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | -0.00 | -0.00 | -0.00 |
| Avg | -0.80 | -0.00 | -0.00 |
| Low | -1.53 | -0.00 | -0.00 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.